Protective Effect of Human Mesenchymal Stem Cells on the Survival of Pancreatic Islets.
Mesenchymal stem cells
Pancreatic islets
Soluble factors
Type-I diabetes
Journal
International journal of stem cells
ISSN: 2005-3606
Titre abrégé: Int J Stem Cells
Pays: Korea (South)
ID NLM: 101497587
Informations de publication
Date de publication:
30 Mar 2020
30 Mar 2020
Historique:
received:
30
07
2019
revised:
09
10
2019
accepted:
17
10
2019
pubmed:
1
1
2020
medline:
1
1
2020
entrez:
31
12
2019
Statut:
ppublish
Résumé
Transplantation of pancreatic islets is an intriguing new therapeutic option to face the worldwide spread problem of Type-I diabetes. Currently, its clinical use is limited by several problems, mainly based on the high number of islets required to restore normoglycaemia and by the low survival of the transplanted tissue. A promising attempt to overcome the limits to such an approach was represented by the use of Mesenchymal Stem Cells (MSC). Despite the encouraging results obtained with murine-derived MSC, little is still known about their protective mechanisms. The aim of the present study was to verify the effectiveness, (besides murine MSC), of clinically relevant human-derived MSC (hMSC) on protecting pancreatic islets, thus also shedding light on the putative differences between MSC of different origin. Threefold kinds of co-cultures were therefore in vitro set up (direct, indirect and mixed), to analyze the hMSC effect on pancreatic islet survival and function and to study the putative mechanisms involved. Although in a different way with respect to murine MSC, also human derived cells demonstrated to be effective on protecting pancreatic islet survival. This effect could be due to the release of some trophic factors, such as VEGF and Il-6, and by the reduction of inflammatory cytokine TNF- Therefore, hMSC confirmed their great clinical potential to improve the feasibility of pancreatic islet transplantation therapy against diabetes.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
Transplantation of pancreatic islets is an intriguing new therapeutic option to face the worldwide spread problem of Type-I diabetes. Currently, its clinical use is limited by several problems, mainly based on the high number of islets required to restore normoglycaemia and by the low survival of the transplanted tissue. A promising attempt to overcome the limits to such an approach was represented by the use of Mesenchymal Stem Cells (MSC). Despite the encouraging results obtained with murine-derived MSC, little is still known about their protective mechanisms. The aim of the present study was to verify the effectiveness, (besides murine MSC), of clinically relevant human-derived MSC (hMSC) on protecting pancreatic islets, thus also shedding light on the putative differences between MSC of different origin.
METHODS AND RESULTS
RESULTS
Threefold kinds of co-cultures were therefore in vitro set up (direct, indirect and mixed), to analyze the hMSC effect on pancreatic islet survival and function and to study the putative mechanisms involved. Although in a different way with respect to murine MSC, also human derived cells demonstrated to be effective on protecting pancreatic islet survival. This effect could be due to the release of some trophic factors, such as VEGF and Il-6, and by the reduction of inflammatory cytokine TNF-
CONCLUSIONS
CONCLUSIONS
Therefore, hMSC confirmed their great clinical potential to improve the feasibility of pancreatic islet transplantation therapy against diabetes.
Identifiants
pubmed: 31887847
pii: ijsc19094
doi: 10.15283/ijsc19094
pmc: PMC7119207
doi:
Types de publication
Journal Article
Langues
eng
Pagination
116-126Références
World J Gastroenterol. 2011 Dec 21;17(47):5150-5
pubmed: 22215938
Int J Stem Cells. 2014 Nov;7(2):127-34
pubmed: 25473450
Eur J Histochem. 2007;51 Suppl 1:1-8
pubmed: 17703587
J Mol Cell Biol. 2011 Apr;3(2):123-31
pubmed: 21278199
Transpl Int. 2009 Dec;22(12):1182-8
pubmed: 19891047
Diabetologia. 2009 Dec;52(12):2653-61
pubmed: 19789851
Diabetes Res Clin Pract. 2009 Oct;86(1):11-5
pubmed: 19679368
Blood. 2005 May 15;105(10):4120-6
pubmed: 15692068
Acta Histochem. 2018 May;120(4):356-362
pubmed: 29622345
Cell Mol Biol Lett. 2013 Jun;18(2):163-86
pubmed: 23430457
PLoS One. 2014 Jan 08;9(1):e84309
pubmed: 24416216
Stem Cell Res Ther. 2014 Jan 10;5(1):5
pubmed: 24411922
Transplant Proc. 2009 Jun;41(5):1797-800
pubmed: 19545731
Semin Pediatr Surg. 2012 Aug;21(3):272-80
pubmed: 22800980
Am J Transplant. 2006 Sep;6(9):2060-8
pubmed: 16827790
Islets. 2013 Mar-Apr;5(2):67-78
pubmed: 23584214
J Exp Clin Cancer Res. 2009 Nov 03;28:141
pubmed: 19883517
Exp Mol Med. 2013 Nov 15;45:e54
pubmed: 24232253
Cytotherapy. 2009;11(5):503-15
pubmed: 19728189
Expert Opin Biol Ther. 2007 Nov;7(11):1627-45
pubmed: 17961088
Blood. 2005 Sep 1;106(5):1755-61
pubmed: 15905186
Cytotherapy. 2011 Jan;13(1):19-29
pubmed: 21142900
Transplantation. 2010 Mar 15;89(5):509-17
pubmed: 20125064
J Cereb Blood Flow Metab. 2007 Oct;27(10):1684-91
pubmed: 17356562
Cell Death Dis. 2010 Apr 22;1:e36
pubmed: 21364643
Ups J Med Sci. 2011 Mar;116(1):8-17
pubmed: 21050099
PLoS One. 2012;7(5):e38189
pubmed: 22666480
Int J Pediatr Otorhinolaryngol. 2018 Oct;113:38-45
pubmed: 30174007
Cell Transplant. 2007 Jan;16(1):1-8
pubmed: 28880676
Exp Neurol. 2017 Feb;288:75-84
pubmed: 27851902
Curr Opin Biotechnol. 2013 Oct;24(5):900-8
pubmed: 23769320
Sci Rep. 2015 Mar 30;5:9322
pubmed: 25818803
J Tissue Eng Regen Med. 2011 Jun;5(6):491-500
pubmed: 21604384
Stem Cells. 2009 Aug;27(8):1954-62
pubmed: 19544427
Exp Ther Med. 2014 Nov;8(5):1389-1396
pubmed: 25289028
Stem Cells. 2012 Aug;30(8):1664-74
pubmed: 22644660
Nat Rev Immunol. 2008 Sep;8(9):726-36
pubmed: 19172693
Blood. 2005 Mar 1;105(5):2214-9
pubmed: 15514012
Cytotherapy. 2007;9(5):427-38
pubmed: 17786604
Int J Biochem Cell Biol. 2008;40(5):815-20
pubmed: 18295530